The onset of heart failure is typically preceded by cardiac hypertrophy, a response of the
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …

The aim of the present study is to identify microRNAs (miRs) with high potential to be used
as biomarkers in plasma and/or serum to clinically diagnose, or provide accurate prognosis …

Pulmonary arterial hypertension (PAH) is a progressive vascular disease with a high
mortality rate. It is characterized by an occlusive vascular remodeling due to a pro …

Right ventricular (RV) heart failure is the leading cause of death in pulmonary arterial
hypertension (PAH). Peroxisome proliferator–activated receptor γ (PPARγ) acts as a …

Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

The pulmonary circulation is a low-resistance, low-pressure, and high-compliance system
that allows the lungs to receive the entire cardiac output. Pulmonary arterial pressure is a …

Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy,
characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and …

Background—Right ventricular (RV) failure is the most important factor of both morbidity and
mortality in pulmonary arterial hypertension (PAH). However, the underlying mechanisms …

Rationale: Right ventricular (RV) fibrosis in pulmonary arterial hypertension contributes to
RV failure. While RV fibrosis reflects changes in the function of resident RV fibroblasts …

Pulmonary hypertension (PH) is a heterogeneous and fatal disease of the lung vasculature,
where metabolic and mitochondrial dysfunction may drive pathogenesis. Similar to the …